Precigen (NASDAQ:PGEN) Stock Rating Upgraded by Zacks Research

Precigen (NASDAQ:PGEN) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

PGEN has been the topic of a number of other reports. HC Wainwright boosted their price target on Precigen from $8.50 to $9.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Thursday, January 22nd. Finally, Wall Street Zen cut shares of Precigen from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $8.50.

Precigen Stock Performance

NASDAQ PGEN opened at $3.42 on Tuesday. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -2.46 and a beta of 1.10. The company has a quick ratio of 3.95, a current ratio of 4.04 and a debt-to-equity ratio of 2.22. The business has a 50-day moving average price of $4.32 and a 200-day moving average price of $4.06. Precigen has a twelve month low of $1.11 and a twelve month high of $5.47.

Insider Activity

In related news, Director Randal J. Kirk sold 1,900,036 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $4.18, for a total value of $7,942,150.48. Following the sale, the director directly owned 341,189 shares in the company, valued at approximately $1,426,170.02. The trade was a 84.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 47.10% of the company’s stock.

Hedge Funds Weigh In On Precigen

Several institutional investors have recently added to or reduced their stakes in PGEN. NBC Securities Inc. bought a new stake in Precigen in the 4th quarter worth approximately $38,000. Mason Investment Advisory Services Inc. purchased a new stake in shares of Precigen during the 4th quarter worth approximately $42,000. Abel Hall LLC bought a new position in shares of Precigen during the 4th quarter valued at approximately $44,000. NewEdge Advisors LLC bought a new position in shares of Precigen during the 4th quarter valued at approximately $45,000. Finally, Asempa Wealth Advisors purchased a new position in shares of Precigen in the fourth quarter valued at $48,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.